The validation of cardiovascular risk scores for patients with type 2 diabetes mellitus

被引:56
作者
van der Leeuw, J. [1 ]
van Dieren, S. [2 ,3 ]
Beulens, J. W. J. [2 ]
Boeing, H. [4 ]
Spijkerman, A. M. W. [5 ]
van der Graaf, Y. [2 ]
van der A, D. L. [5 ]
Noethlings, U. [6 ]
Visseren, F. L. J. [1 ]
Rutten, G. E. H. M. [2 ]
Moons, K. G. M. [2 ]
van der Schouw, Y. T. [2 ]
Peelen, L. M. [2 ]
机构
[1] Univ Med Ctr Utrecht, Dept Vasc Med, NL-3508 GA Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Clin Res Unit, NL-1105 AZ Amsterdam, Netherlands
[4] German Inst Human Nutr Potsdam Rehbrucke, Dept Epidemiol, Nuthetal, Germany
[5] Natl Inst Publ Hlth & Environm RIVM, Ctr Nutr Prevent & Hlth Serv, Bilthoven, Netherlands
[6] Univ Bonn, Dept Nutr & Food Sci, Bonn, Germany
关键词
CORONARY-HEART-DISEASE; EXTERNAL VALIDATION; PREDICTION MODELS; VASCULAR-DISEASE; FRAMINGHAM; ENGINE; DERIVATION; EQUATIONS; EVENTS; PEOPLE;
D O I
10.1136/heartjnl-2014-306068
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Various cardiovascular prediction models have been developed for patients with type 2 diabetes. Their predictive performance in new patients is mostly not investigated. This study aims to quantify the predictive performance of all cardiovascular prediction models developed specifically for diabetes patients. Design and methods Follow-up data of 453, 1174 and 584 type 2 diabetes patients without pre-existing cardiovascular disease (CVD) in the EPIC-NL, EPIC-Potsdam and Secondary Manifestations of ARTerial disease cohorts, respectively, were used to validate 10 prediction models to estimate risk of CVD or coronary heart disease (CHD). Discrimination was assessed by the c-statistic for time-to-event data. Calibration was assessed by calibration plots, the Hosmer-Lemeshow goodness-of-fit statistic and expected to observed ratios. Results There was a large variation in performance of CVD and CHD scores between different cohorts. Discrimination was moderate for all 10 prediction models, with c-statistics ranging from 0.54 (95% CI 0.46 to 0.63) to 0.76 (95% CI 0.67 to 0.84). Calibration of the original models was poor. After simple recalibration to the disease incidence of the target populations, predicted and observed risks were close. Expected to observed ratios of the recalibrated models ranged from 1.06 (95% CI 0.81 to 1.40) to 1.55 (95% CI 0.95 to 2.54), mainly driven by an overestimation of risk in high-risk patients. Conclusions All 10 evaluated models had a comparable and moderate discriminative ability. The recalibrated, but not the original, prediction models provided accurate risk estimates. These models can assist clinicians in identifying type 2 diabetes patients who are at low or high risk of developing CVD.
引用
收藏
页码:222 / 229
页数:8
相关论文
共 50 条
  • [31] Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus
    Brownrigg, Jack R. W.
    de Lusignan, Simon
    McGovern, Andrew
    Hughes, Cian
    Thompson, Matthew M.
    Ray, Kausik K.
    Hinchliffe, Robert J.
    HEART, 2014, 100 (23) : 1837 - +
  • [32] Asymmetric dimethylarginine as a risk factor for cardiovascular disease in Japanese patients with type 2 diabetes mellitus
    Kanazawa, Ippei
    Yano, Shozo
    Notsu, Yoshitomo
    Yamaguchi, Toru
    Nabika, Toru
    Sugimoto, Toshitsugu
    CLINICAL ENDOCRINOLOGY, 2011, 74 (04) : 467 - 472
  • [33] The Clinical Implications of the CHICAGO Study for the Management of Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus
    Polonsky, Tamar
    Mazzone, Theodore
    Davidson, Michael
    TRENDS IN CARDIOVASCULAR MEDICINE, 2009, 19 (03) : 94 - 99
  • [34] IMPACT OF ANTIDIABETIC THERAPY ON THE RISK OF CARDIOVASCULAR DISEASES AND THEIR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Ametov, A. S.
    Pyanykh, O. P.
    Chernikova, N. A.
    TERAPEVTICHESKII ARKHIV, 2010, 82 (08) : 71 - 75
  • [35] Comparison of different vascular risk engines in the identification of type 2 diabetes patients with high cardiovascular risk
    Rodriguez-Poncelas, Antonio
    Coll-de-Tuero, Gabriel
    Saez, Marc
    Garrido-Martin, Jose M.
    Millaruelo-Trillo, Jose M.
    Barrot de-la-Puente, Joan
    Franch-Nadal, Josep
    BMC CARDIOVASCULAR DISORDERS, 2015, 15
  • [36] Development and validation of a risk score for hospitalization for heart failure in patients with Type 2 Diabetes Mellitus
    Xilin Yang
    Ronald C Ma
    Wing-Yee So
    Alice P Kong
    Gary T Ko
    Chun-Shun Ho
    Christopher W Lam
    Clive S Cockram
    Peter C Tong
    Juliana C Chan
    Cardiovascular Diabetology, 7
  • [37] Target Values of Cardiovascular Risk Factors Are Not Associated with All-Cause Mortality in Patients with Type 2 Diabetes Mellitus
    Pacilli, Antonio
    Lamacchia, Olga
    Fontana, Andrea
    Copetti, Massimiliano
    Cignarelli, Mauro
    Trischitta, Vincenzo
    De Cosmo, Salvatore
    PLOS ONE, 2015, 10 (04):
  • [38] An explainable XGBoost-based approach towards assessing the risk of cardiovascular disease in patients with Type 2 Diabetes Mellitus
    Athanasiou, Maria
    Sfrintzeri, Konstantina
    Zarkogianni, Konstantia
    Thanopoulou, Anastasia C.
    Nikita, Konstantina S.
    2020 IEEE 20TH INTERNATIONAL CONFERENCE ON BIOINFORMATICS AND BIOENGINEERING (BIBE 2020), 2020, : 859 - 864
  • [39] Risk for cardiovascular events in an Italian population of patients with type 2 diabetes
    Pellegrini, E.
    Maurantonio, M.
    Giannico, I. M.
    Simonini, M. S.
    Ganazzi, D.
    Carulli, L.
    D'Amico, R.
    Baldini, A.
    Loria, P.
    Bertolotti, M.
    Carulli, N.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2011, 21 (11) : 885 - 892
  • [40] Effects of Combination Lipid Therapy in the Management of Patients With Type 2 Diabetes Mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
    Tonkin, Andrew M.
    Chen, Lei
    CIRCULATION, 2010, 122 (08) : 850 - 852